Development of Albumin-Binding Camptothecin Prodrugs Using a Peptide Positional Scanning Library

• Published in: Bioconjugate chemistry 2007-11, Vol.18 (6), p.1786-1799
• Main Authors: Schmid, Björn, Warnecke, André, Fichtner, Iduna, Jung, Manfred, Kratz, Felix
• Format: Article
• Language: English
• Subjects: Albumins - chemistry; Amino acids; Animals; Camptothecin - chemistry; Camptothecin - pharmacology; Cancer; Cell Line, Tumor; Chemotherapy; Health; Humans; Mice; Mice, Nude; Molecular Structure; Neoplasms - pathology; Peptide Library; Peptides; Prodrugs - chemistry; Prodrugs - pharmacology; Tumors; Xenograft Model Antitumor Assays
• ISSN: 1043-1802; 1520-4812
• DOI: 10.1021/bc0700842

Designing truly tumor-specific prodrugs remains a challenge in the field of cancer chemotherapy. As a new strategy, we incubated homogenates of a spectrum of human colon tumor xenografts with a fluorogenic positional scanning tetrapeptide library in order to identify peptide sequences that are preferentially cleaved by colon tumors. Our screening experiments at pH 7.4 revealed that Met, Leu, and Lys were preferred amino acids in the position P1 and Tyr, Phe, and Met in P2, whereas in P3 and P4, the cleavage profiles were less characteristic. However, similar results were obtained when testing breast tumor material and homogenates from healthy murine organs. On the basis of these results, we developed albumin-binding camptothecin (CPT) prodrugs of the general formula EMC-Arg-P4-P3-P2-P1-Ala-CPT (EMC = 6-maleimidocaproic acid) that incorporated two peptide linkers: H-Arg-Ala-Phe-Met-OH and H-Arg-Phe-Tyr-Met-OH (P4-P3-P2-P1). The incorporation of two arginine residues rendered the prodrugs water-soluble (>7 mg/mL), while the use of alanine as an amino acid spacer proved to be beneficial for the release of the active agent. Incubation studies with homogenates of HT-29 colon tumor tissue and murine spleen, liver, and kidneys demonstrated cleavage of the peptide linker with CPT–peptide derivatives and CPT being the major cleavage products. Although the peptide sequence is not selectively cleaved in colon tumors, an in vivo study in a HT-29 xenograft model showed that the prodrug EMC-Arg-Arg-Ala-Phe-Met-Ala-CPT demonstrated enhanced antitumor efficacy when compared to CPT [(T/C max: 17% for the prodrug (2 × 12.5 mg/kg CPT equivalents) and 40% for CPT (3 × 12.5 mg/kg)].